RVx 1001
Alternative Names: RVx-1001Latest Information Update: 30 Dec 2021
Price :
$50 *
At a glance
- Originator Southern Illinois University School of Medicine; University of Kansas
- Developer Rational Vaccines
- Class Attenuated vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Herpes simplex virus type 1 infections
Most Recent Events
- 28 Dec 2021 Immunogenicity data from preclinical trials in Herpes simplex virus type 1 infections released by Rational Vaccines
- 28 Dec 2021 Rational Vaccines plans a clinical trial for Herpes simplex virus type 1 infections (Prevention) (IM)
- 31 May 2015 Herpes simplex virus mutant Infected Cell Protein licensed to Rational Vaccines by May 2015